Like many other big pharma companies, Roche Holding AG spent 2023 looking for late-stage assets to meet their short-term needs ahead of a looming patent cliff. With several large deals now signed, the company can return to its usual approach, characterized by an interest in assets throughout the development continuum.
Key Takeaways
-
After focusing on late-stage assets in 2023, Roche is back to a more holistic approach to dealmaking.
-
The company is willing to go outside of its core therapeutic areas
“In 2024, we’re going to see a balance between preclinical research technologies as well as preclinical programs that are anywhere from the mid-stage of research to those just about to go into human studies, and then clinical programs as well,” James Sabry, global head
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
